Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Sirolimus (rapamycin) is an immunosuppressant that blocks mTOR, a protein that controls cell growth and division, so T cells cannot multiply. It is used to prevent rejection after kidney transplants, for the rare lung disease lymphangioleiomyomatosis, and on drug-coated stents to keep heart arteries open. Blood levels are monitored. It is sold as Rapamune, among other names.
Sirolimus is broken down by CYP3A4 and CYP3A5 and pumped out of cells by ABCB1, the same genes studied for tacrolimus. Studies find lower levels in people with at least one working CYP3A5 copy (*1), but the effect is smaller than for tacrolimus and there is no CPIC or DPWG guideline. Studies have also looked at ABCB1, CYP3A4 and POR, with weaker evidence.
Every published finding on gene variants and Sirolimus. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
CYP3A5 CYP3A5*1, CYP3A5*3: Level 3. Metabolism/PK: Transplantation. 6.
TCF7L2 rs7903146: Level 3. Toxicity: Kidney Transplantation, Liver transplantation. 3.
CYP3A5 CYP3A5*1, CYP3A5*3: Level 3. Dosage. 2.
IL10 rs1800896: Level 3. Metabolism/PK: Kidney Transplantation. 1.
Studies of how quickly the body processes this medication.
Studies of how much of the drug people needed or tolerated.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com